<DOC>
	<DOC>NCT02251184</DOC>
	<brief_summary>Comparison of pharmacokinetics of dipyridamole administered as Aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.</brief_summary>
	<brief_title>Pharmacokinetics of Dipyridamole Administered as AggrenoxÂ® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Healthy subjects as determined by results of screening Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation Age 40 65 years, inclusive, at time of Visit 1 Stomach pH &gt; 4.0 on three consecutive measurements separated by at least five minutes, measured at Visits 3B and 5B prior to dosing with Aggrenox or dipyridamoleaspirin (DPASA) Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and considered by the investigator to be of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders considered by the investigator to be of clinical relevance History of gastrointestinal ulcer, perforation or bleeding Surgery of the gastrointestinal tract (except appendectomy) Diseases of the central nervous system (such as epilepsy), neurological disorders, or psychiatric disorders Chronic or relevant acute infections. Screening tests will be performed for HIV, hepatitis B, and hepatitis C History of hypersensitivity to Aggrenox or any of the components or excipients Intake of drugs with a long dominant halflife (&gt;24 hours) 1 month or less prior to Visit 1 Use of any drugs which might influence the results of the trial ten days or less prior to Visit 1 Participation in another trial with an investigational drug 1 month or less prior to Visit 1 Known alcohol abuse Known drug abuse (a drug screening test will be performed at Visits 1, 3, and 5) Blood donation 1 month or less prior to Visit 1 Excessive physical activities five days or less prior to Visit 1 History of hemorrhagic diathesis History of bronchial asthma Any laboratory value outside the reference range, considered by the investigator to be of clinical relevance For female subjects: Nursing Pregnancy Positive pregnancy test No adequate contraception (adequate contraception includes sterilization, intrauterine device, or oral contraceptives) Inability to maintain adequate contraception during the whole study period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>